Endurance Wealth Management’s Arcturus Therapeutics ARCT Stock Holding History

Endurance Wealth Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$5K	Hold	165	–	–	﹤0.01%	544
2023 Q1	$4K	Hold	165	–	–	﹤0.01%	554
2022 Q4	$3K	Hold	165	–	–	﹤0.01%	550
2022 Q3	$2K	Hold	165	–	–	﹤0.01%	551
2022 Q2	$3K	Hold	165	–	–	﹤0.01%	554
2022 Q1	$4K	Hold	165	–	–	﹤0.01%	560
2021 Q4	$6K	Hold	165	–	–	﹤0.01%	536
2021 Q3	$8K	Hold	165	–	–	﹤0.01%	541
2021 Q2	$5K	Hold	165	–	–	﹤0.01%	558
2021 Q1	$7K	Buy	+165	New	+$9.84K	﹤0.01%	555

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Endurance Wealth Management's ARCT Position: Q2 2023 in Review

Endurance Wealth Management held its Arcturus Therapeutics (ARCT) position steady in Q2 2023 at 165 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #544.

Endurance Wealth Management first reported a position in ARCT in Q1 2021 and has held it in 10 quarters since. The position peaked at $8K in Q3 2021. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2023.

Endurance Wealth Management held 165 shares of Arcturus Therapeutics worth $5K as of Q2 2023.
Endurance Wealth Management left its Arcturus Therapeutics share count unchanged in Q2 2023.
Arcturus Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #544 holding.
Endurance Wealth Management first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 10 quarters since.
Endurance Wealth Management's Arcturus Therapeutics position peaked at $8K in Q3 2021.
143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.